Literature DB >> 19798722

Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum.

Richard M Ransohoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19798722     DOI： 10.1002/ana.21850

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  4 in total

1.  Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.

Authors:  N Schwab; J C Ulzheimer; R J Fox; T Schneider-Hohendorf; B C Kieseier; C M Monoranu; S M Staugaitis; W Welch; S Jilek; R A Du Pasquier; W Brück; K V Toyka; R M Ransohoff; H Wiendl
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

2.  Cancer and multiple sclerosis in the era of disease-modifying treatments.

Authors:  Christine Lebrun; Patrick Vermersch; David Brassat; Gilles Defer; Lucien Rumbach; Pierre Clavelou; Marc Debouverie; Jérôme de Seze; Sandrine Wiertlevsky; Olivier Heinzlef; Ayman Tourbah; Agnes Fromont; Marc Frenay
Journal:  J Neurol       Date:  2011-02-04       Impact factor: 4.849

3.  Bowman-Birk Inhibitor attenuates experimental autoimmune encephalomyelitis by delaying infiltration of inflammatory cells into the CNS.

Authors:  Hong Dai; Bogoljub Ciric; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

Review 4.  Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

Authors:  Joachim Havla; Ingo Kleiter; Tania Kümpfel
Journal:  Ther Clin Risk Manag       Date:  2013-10-03       Impact factor: 2.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.